TRAPS-Syndrom ohne Nachweis einer Mutation im TNFRSF1A-Gen mit gutem Ansprechen auf Anakinra
暂无分享,去创建一个
[1] C. Wouters,et al. Recommendations for the management of autoinflammatory diseases , 2015, Pediatric Rheumatology.
[2] P. Voulgari,et al. Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. , 2015, Clinical and experimental rheumatology.
[3] E. Silvestri,et al. Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome , 2014, Clinical Rheumatology.
[4] G. Gualdi,et al. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. , 2013, Dermatology online journal.
[5] S. Özen,et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review , 2012, Annals of the rheumatic diseases.
[6] D. Kastner,et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. , 2012, Arthritis and rheumatism.
[7] C. Baldari,et al. Role of Etanercept in the Treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Personal Experience and Review of the Literature , 2010, International journal of immunopathology and pharmacology.